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ABSTRACT: Tankyrase 1 and 2 (TNKS1/2) catalyze post-
translational modification by poly-ADP-ribosylation of a plethora
of target proteins. In this function, TNKS1/2 also impact the
WNT/β-catenin and Hippo signaling pathways that are involved in
numerous human disease conditions including cancer. Targeting
TNKS1/2 with small-molecule inhibitors shows promising
potential to modulate the involved pathways, thereby potentiating
disease intervention. Based on our 1,2,4-triazole-based lead
compound 1 (OM-1700), further structure−activity relationship
analyses of East-, South- and West-single-point alterations and
hybrids identified compound 24 (OM-153). Compound 24
showed picomolar IC50 inhibition in a cellular (HEK293) WNT/β-catenin signaling reporter assay, no off-target liabilities, overall
favorable absorption, distribution, metabolism, and excretion (ADME) properties, and an improved pharmacokinetic profile in mice.
Moreover, treatment with compound 24 induced dose-dependent biomarker engagement and reduced cell growth in the colon
cancer cell line COLO 320DM.
■ INTRODUCTION
Tankyrase 1 and tankyrase 2 (TNKS1/2) are members of the
poly(ADP-ribose) polymerase (PARP) family of enzymes that
regulate the turnover of specific target proteins through
covalently linking the cellular redox metabolite NAD+ to target
proteins in a process called poly-ADP-ribosylation (PARyla-
tion). The PAR chain produced in this post-translational
modification is subsequently recognized by the E3 ubiquitin
ligase ring finger protein 146 (RNF146) leading to poly-
ubiquitination of the PARylated target proteins followed by
proteasomal degradation.1−4 Independent of their catalytic
activity, TNKS1/2 also provides scaffolding functions that are
important in the formation of protein complexes.5−8 TNKS1/2
PARylate a plethora of target proteins including peroxisome
proliferator-activated receptor-gamma coactivator 1 α (PGC-
1α), telomeric repeat binding factor 1 (TRF1), phosphatase
and tensin homologue (PTEN), AMP-activated protein kinase
(AMPK), SRY-box transcription factor 9 (SOX9), and SH3
domain binding protein 2 (SH3BP2).3,9−15 In particular,
TNKS1/2 regulate the turnover of AXIN1, AXIN2 (AXIN1/
2) and of angiomotin (AMOT) proteins at the crossroad of the
elementary wingless-type mammary tumor virus integration
site (WNT)/β-catenin and Hippo signaling pathways,
respectively.3,14,16,17 Hence, controlling the catalytic activity
of tankyrase by pharmacological intervention provides an
attractive tool for reducing WNT/β-catenin and Hippo
signaling.18,19
Multiple potent TNKS1/2 inhibiting small molecules,
including bicyclic lactams, compounds based on heteroalicyclic
amide scaffolds, tricyclic fused ring systems and 1,2,4-triazole
scaffolds, have been identified. These compounds block the
catalytic domain of TNKS1/2, either by binding with high
selectivity to the adenosine binding pocket (which differs from
other members of the PARP family) or by binding to the more
conserved nicotinamide pocket. The latter binding mode
results in a lower selectivity across the PARP family. Other
compounds target both pockets in the catalytic domain.16,20−37
Inhibitors based on the 1,2,4-triazole scaffold such as JW74,38
G007-LK,21 OD336,28 and OM-1700 (1)39 target the
adenosine binding pocket of the TNKS1/2 catalytic domain
with high selectivity and are therefore able to display selectivity
over other members of the PARP family.
Despite the significant progress in developing TNKS1/2
inhibitors, there is currently no viable TNKS1/2 specific
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inhibitor in clinical practice for any disease indication.
Concerns that have hampered clinical trials of TNKS1/2
inhibitors include earlier reports indicating intestinal tox-
icity40,41 and bone loss in mouse models,13 although other
studies show a beneficial effect of tankyrase inhibition on
fracture healing.42 Nevertheless, mice that have been treated
for an extended time with a moderate dose of a tankyrase
inhibitor have not shown visible adverse effects.43 Ongoing
studies suggest that it is possible to overcome a potential
biotarget toxicity and recently the tankyrase inhibitors E7449
(a dual inhibitor of PARP1/2 and TNKS1/2) and STP1002
have entered clinical trials with dose escalation studies in
patients with advanced solid tumors.44,45 This clearly illustrates
the potential of TNKS1/2 inhibitors and justifies the
development of drugs directed toward TNKS1/2 inhibition
with high potency and an optimized pharmacokinetic (PK)
profile.
Here, we further optimize compounds based on the 1,2,4-
triazole series as landmark compounds21,28,38,39 and we present
compounds reaching picomolar IC50 values in a cellular WNT/
β-catenin signaling reporter assay, while also showing
optimized absorption, distribution, metabolism, excretion
(ADME), and pharmacokinetic (PK) properties.
■ RESULTS AND DISCUSSION
Compound Design Strategy. Starting from the pre-
viously described lead compound 1 (Figure 1)39 and having
developed synthetic methodologies for preparing compound
iterations in a modular fashion (see Supporting Experimentals
for the general scheme of synthesis), we aimed at further
improving the potency of tankyrase inhibition and optimizing
ADME and pharmacokinetic properties of 1. Optimization was
motivated by the highly potent compounds discovered during
the development of 1 (e.g., compounds 16, 21, and 27 as
numbered in our preceding paper,39 see Chart S-1). In
addition to this, the pharmacokinetic properties of 1, primarily
its half-life and exposure, necessitated further improvements.
In the process of making next-generation derivatives based
on these previous compounds,39 we revisited South-, East-, and
West-single-point mutations and hybrids thereof. From these
structures, we selected six compounds based on their cellular
activity and on the diversity of their molecular architecture.
The properties of these six shortlisted compounds were
evaluated in mouse peroral pharmacokinetic studies and
compared with that of compound 1. The best compound of
this set was selected and further evaluated with respect to early
ADME properties, off-target effects, binding affinity in the
catalytic pocket of the TNKS2 protein, as well as inhibition of
WNT/β-catenin signaling and proliferation in the colon cancer
cell line COLO 320DM. The results from these experiments
culminated in the identification of a new 1,2,4-triazole based
lead tankyrase inhibitor.
Structure−Activity Relationship (SAR) Investigation
and Biological Evaluation. To further explore the SAR of
the West- and South-regions of 1, single-point modifications
departing from 1 were synthesized (Table 1). From these
compounds, we concluded that a gain in potency in our in vitro
TNKS2 assay and cell-based WNT/β-catenin signaling assay
cannot be attained with compounds possessing the East 2-
pyridyl group while changing South/West groups, and we
therefore focused on compounds with annulated aromatic
heterocycles such as naphthyridines and quinoxalines46 (Table
2). Such variations enabled picomolar potencies as these
moieties are able to form a significantly more efficient π−π-
stacking interaction with His1048 and an additional hydro-
phobic interaction with Phe1035 as evidenced by the obtained
co-crystal structures.39
First, we explored a series based on the East-side 1,5-
naphthyridine, either with or without a 3-fluoro substituent
(Table 2). Since compound 15a was impaired by a high
metabolic instability in mouse microsomes, we aimed at
making the structure metabolically more stable by increasing
the polarity with the introduction of a South-pyridyl-
substitution and compounds 16−18 (Table 2) were prepared.
In general, more polar compounds are expected to show
greater metabolic stability. Compounds with such a South-
pyridyl, however, proved to be less potent in the cellular
WNT/β-catenin signaling reporter assay compared to 15a and
only compound 18b with an IC50 value of 6 nM was selected
for further characterization (Table 2). To improve potency of
compounds 16−18 as earlier observed, a bicyclo[1.1.1]pentane
core as an alternative to the cyclobutane influenced activity
favorably (see, e.g., compound 19 as numbered in our
preceding paper39). Unfortunately, here, compounds built on
this bicyclo[1.1.1]pentane core lacked picomolar cellular
activity when combined with a South-pyridyl moiety
(compounds 19−21, Table 2) and these South-pyridyl
structures were abandoned. Furthermore, a South-methyl
thiophene group was introduced as a phenyl bio-isostere47
(compounds 22 and 23, Table 2), resulting in potent inhibitors
of which compound 22a was selected for further evaluation.
Finally, the introduction of an East quinoxaline moiety
instead of the naphthyridine group (compound 24) again led
to picomolar cellular activity (IC50 = 0.63 nM), and we
prepared further variations based on a quinoxaline core to
interrogate this part of the pharmacophore. Variations of lead
24 by four fluorine- and methyl-substituted quinoxalines
showed similar inhibitory activity (compounds 25−28, Table
3) but by varying the West-moiety, highly efficacious inhibitors
could be obtained with the quinoxaline East-group. Three of
these compounds were selected for further profiling (com-
pounds 30b, 31a, and 31b). This resulted in a short list of six
inhibitors with relatively high structural diversity (Figure 2).
Next, the set of six shortlisted compounds (Figure 2) was
subjected to mouse peroral pharmacokinetic (PK) analyses and
compared with 1 (Table 4). Here, compounds 22a and 18b
displayed a decreased exposure (area under the curve, AUC)
Figure 1. Lead compound 1 (OM-1700) and main modifications.
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while compound 31a showed an AUC similar to 1. In contrast,
compound 30b showed a high AUC, however, with a small
volume of distribution (0.33 L/kg), and consequently, none of
these compounds were selected for further evaluation.
Further, compounds 31b and 24 showed improved
pharmacokinetic properties compared to 1 (Table 4). The
AUCs for 31b and 24 were similar and about twice as high
compared to the AUC for 1. The peak value (Cmax) of
exposure of 24 was approximately 3 times lower compared to
the peak value for compound 31b. In addition, 24 showed a
more favorable volume of distribution and solubility compared
to these data for compound 31b. Compared to 1, compound
24 possesses an AUC about twice as high and a peak value of
about 60% of that of 1 resulting in a higher exposure with a
lower peak level. In addition to this, efficacy in the cellular
WNT/β-catenin signaling reporter assay was approximately 30
times higher while the clearance of 24 was about half of that of
1.
In summary, based on the overall improved mouse PK
profile and the enhanced potency in the cellular WNT/β-
catenin signaling reporter assay, compound 24 was designated
as the best derivative.
Table 1. West Variations of 1 (OM-1700)a
aThe IC50 values of the compounds of this work were determined with both the TNKS2 biochemical assay (quadruplicates used for each
concentration tested, 95% confidence intervals are given in parentheses) and the cellular (HEK293) WNT/β-catenin signaling reporter assay
(triplicates used for each concentration tested, T/F-tests were performed for the IC50 curve fitting; all p > 0.95).
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Subsequently, compound 24 was further characterized and
compared to benchmark structure 1 with respect to early
ADME properties and off-target effects. Tested ADME
parameters such as kinetic solubility, Caco-2 permeability
and efflux, microsomal stabilities, mouse plasma stability, and
mouse plasma protein binding were found to be in line with 1,
while solubility was somewhat lower although in an acceptable
range (Table 5).
Next, we solved a co-crystal structure of TNKS2-24
demonstrating that 24 binds to the NAD+ cleft of the catalytic
domain in a similar manner to the previously reported
analogue 139 (Figure 3). The observed electron density is
clear for the compound except for an apparently mobile ethoxy
group extending toward the nicotinamide site. The previously
identified hydrogen bonds of the scaffold39 were once more
observed between 24 and the Tyr1060 and Asp1045
backbones, as well as with a water molecule. The quinoxaline
moiety is forming π−π stacking interactions with both His1048
and Phe1035 providing improved binding affinity compared
with that of 1.
Finally, to complete the analysis of compound 24, COLO
320DM cells, likely of neuroendocrinal origin,48 were treated
with various doses of 24 to evaluate the efficacy in reducing
canonical WNT/β-catenin signaling and the potential as an
antiproliferative agent in this cancer cell line. Previously, we
have shown that tankyrase inhibition can block WNT/β-
catenin signaling and attenuate proliferation and viability in
cancer cell lines in vitro and in vivo, including COLO 320DM
that is commonly used for testing tankyrase inhibitors.28,39,49,50
Treatment of COLO 320DM cells with 24 decreased viability
with a GI50 value of 10.1 nM and a GI25 value of 2.5 nM (for 1,
these values were 650 and 94 nM, respectively39), while
APCwild‑type RKO cells as a control colon cancer line were only
modestly affected by treatment with compound 24 (Figure
4a). As previously observed upon tankyrase inhibition,49,51
treatment with 24 dose-dependently either increased or
decreased the TNKS1/2 protein levels (Figure 4b). Com-
pound 24 also stabilized AXIN1 and AXIN2 proteins and
reduced the level of transcriptionally active β-catenin (non-
phosphorylated) in both cytoplasmic and nuclear fractions
(Figure 4b). In addition, real-time qRT-PCR analyses revealed
Table 2. East Naphthyridines and Quinoxalinesa
aThe IC50 values of the compounds of this work were determined with both the TNKS2 biochemical assay (quadruplicates used for each
concentration tested, 95% confidence intervals are given in parentheses) and the cellular (HEK293) WNT/β-catenin signaling reporter assay
(triplicates used for each concentration tested, T/F-tests were performed for the IC50 curve fitting; all p > 0.95). * indicates a shortlisted
compound. # averages of multiple independent measurements; standard error of the means (SEMs) are shown in Table 5.
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reduced levels of transcripts of the WNT/β-catenin signaling
target genes AXIN2, DKK1, NKD1, and APCDD1 in a dose-
dependent manner (Figure 4c). Collectively, these results
showed that 24 both potently and specifically can inhibit
WNT/β-catenin signaling activity and block proliferation in
COLO 320DM cells.
Table 3. East Quinoxaline Variationsa
aThe IC50 values of the compounds of this work were determined with both the TNKS2 biochemical assay (quadruplicates used for each
concentration tested, 95% confidence intervals are given in parentheses) and the cellular (HEK293) WNT/β-catenin signaling reporter assay
(triplicates used for each concentration tested, T/F-tests were performed for the IC50 curve fitting; all p > 0.95). * indicates shortlisted compound.
# averages of multiple independent measurements; SEMs are shown in Table 5.
Figure 2. Short list of six compounds and 1 including their respective biochemical TNKS2 and cellular (HEK293) WNT/β-catenin signaling
reporter assays IC50 values in nM. clog P and tPSA (in Å
2) as calculated by DataWarrior v5.5.0. Moieties in color were different from 1.
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■ CONCLUSIONS
In this further development of our structure-guided lead
optimization program of 1,2,4-triazole-based tankyrase inhib-
itors, we have extensively improved previous lead compound 1
to lead candidate compound 24.52 We showed that compound
24 possesses improved binding affinity in the catalytic pocket
of the TNKS2 protein with concurrently modest selectivity
over TNKS1, picomolar IC50 activity in the cellular WNT/β-
catenin signaling reporter assay, a clean off-target safety profile,
good ADME properties, an optimized mouse PK profile, and
potent inhibition of WNT/β-catenin signaling and prolifer-
ation in COLO 320DM. These results justify testing
compound 24 in a pharmacodynamics setting as well as in
toxicity models (publication pending).
■ EXPERIMENTAL SECTION
General Methods. NMR spectra were recorded on a 400 MHz
spectrometer with tetramethylsilane as internal standards. Coupling
constants are given in hertz. Peaks are reported as singlet (s), doublet
(d), triplet (t), quartet (q), quintet (p), sextet (h), septet (hept),
multiplet (m), or a combination thereof; br stands for broad.
Liquid chromatography/mass spectroscopy (LC/MS) chromato-
grams mass spectra were recorded using electrospray ionization (ESI)
in positive or negative ionization mode on Agilent 1260 Bin: pump,
G1312B, degasser; autosampler; ColCom; DAD G1315C; MSD
G6130B ESI; eluent A, acetonitrile; eluent B, 10 mM ammonium
bicarbonate in water (base mode) or 0.1% formic acid in water (acid
mode). High-resolution mass spectra (HRMS) were recorded with an
LC-MS Q Exactive Focus high-resolution mass spectrometer
(Thermo Scientific). Calibration was done with the Pierce calibration
solutions containing 1-butylamine, caffeine, MRFA, and Ultramark
1621 (positive mode) and the Pierce calibration solution containing
sodium dodecyl sulfate, sodium taurocholate, and Ultramark 1621
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1 (OM-1700)39 0.67 0.25 3203 2384 2388 0.69 2.03 2.09 >80
18b 1.00 0.25 285 319 322 1.56 22.4 15.6 >80
22a 1.17 0.25 779 543 547 1.39 15.5 9.14 50
24 (OM-153) 1.50 0.5 1967 4945 5038 2.39 2.15 0.99 31
30b 0.69 0.5 6512 15 083 15 105 1.93 0.33 0.33 >80
31a 0.76 0.25 2770 3401 3404 1.24 1.61 1.47 >80
31b 0.59 0.25 5796 5313 5316 1.47 0.80 0.94 13
Table 5. Profiling of Compound 24
parameter 1 (OM-1700) 24 (OM-153)
efficacy
TNKS1 (IC50, nM (pIC50 ± SEM))
a 127 (6.90 ± 0.05) 13 (7.90 ± 0.054)
TNKS2 (IC50, nM (pIC50 ± SEM))
a 14 (7.85 ± 0.04) 2.0 (8.71 ± 0.069)
HEK293 reporter assay (IC50, nM (pIC50 ± SEM)) 19 (7.75 ± 0.067) 0.63 (9.22 ± 0.037)
COLO 320DM/RKO cells (GI50, nM) 650/>10 000 10/>10 000
ADME
kinetic solubility PBS pH = 7 (μM) >80 31
Caco-2 A−B: Papp (10−6 cm/s) 39.5 40.5
Caco-2 efflux ratio 0.61 0.64
microsomal stability human/mouse/dog CLint (μL/min/mg protein) <5/27/nd 18/22/3.8
mouse plasma stability t1/2 (min) >120 >120
mouse PPB (%) 93.92 98.58
off-target
PARPsb PARP1/2/3/4/10/12/14/15 (IC50, μM) >10 >10
hERG inhibition (IC50, μM) >25 >25
Ames test nongenotoxic nongenotoxic
CYP3A4 inhibition (IC50, μM) >25 >25
CYP induction (human PXR) nd nonactivatorbc
Cerep Safety panel 44 targets@10 μM (inhibition) clean, (A2A, 53%) clean, (all <50%)
mouse pharmacokinetics
PO PK mouse t1/2 (h) 0.67 1.5
PO PK mouse Cmax (ng/mL) 3202 1967
PO PK mouse CL (L/h/kg) 2.09 0.99
PO PK mouse Vd (L/kg) 2.03 2.15
PO PK mouse AUC 0 → t (ng/mL) 2384 4945
calculated propertiesd
MW (g/mol) 458.5 509.6
clog P 3.1 3.4
tPSA 95 108
aSee Figure 1, Supporting Information. bSee Table 1, Supporting Information. cHighest concentration, 100 μM. dCalculated by DataWarrior
v5.5.0.
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(negative mode). Analysis: 1 μL of a 10 μg/mL sample in MeCN/
DMSO 99:1 is injected and data are acquired under full MS mode
(resolution 70 000 FWHM at 200 Da) over the mass range m/z of
150−2000. Standard ESI conditions compatible with the flow rate are
applied: spray voltage, 3.5 kV; auxiliary gas heater temperature, 463
°C; capillary temperature, 280 °C; sheath gas, 58; auxiliary gas, 16;
sweep gas, 3; S-lens radio frequency (RF) level, 50. Mass scan range is
150−2000 m/z. Mass resolution is set at 70 000 (<3 ppm mass
accuracy). Data are evaluated using Xcalibur Qual Browser version
4.2.47 (Thermo Fisher).
All test compounds were >95% pure by LC/MS and 1H NMR
analyses. All spectra as well as preparation of the intermediates and
general procedures are given in the Supporting Experimentals.
N-(trans-3-(5-(5-Cyclopropoxypyridin-2-yl)-4-(2-fluorophenyl)-
4H-1,2,4-triazol-3-yl)cyclobutyl)picolinamide (7). The title com-
pound was prepared according to general procedure F as a white solid
(24.3 mg, 75%). LC/MS (ESI) m/z for C26H23N6O2F 470
(calculated) 471 ([M + H]+, found). 1H NMR (400 MHz, CDCl3)
δ 8.56−8.49 (m, 1H), 8.26−8.13 (m, 3H), 7.99 (s, 1H), 7.83 (td, J =
7.7, 1.7 Hz, 1H), 7.50−7.37 (m, 3H), 7.24−7.14 (m, 3H), 4.82−4.71
(m, 1H), 3.74 (tt, J = 6.1, 3.1 Hz, 1H), 3.46 (tt, J = 10.3, 5.3 Hz, 1H),
3.11−2.96 (m, 2H), 2.52−2.35 (m, 2H), 0.84−0.71 (m, 4H). HRMS
m/z [M + H]+: 471.19393 (calculated), 471.1929 (found), Δ = −2.28
ppm.
N-(trans-3-(4-(2-Fluorophenyl)-5-(5-isopropoxypyridin-2-yl)-4H-
1,2,4-triazol-3-yl)cyclobutyl)picolinamide (8). The title compound
was prepared according to general procedure F as a white solid (18.3
mg, 77%). LC/MS (ESI) m/z for C26H25N6O2F 472 (calculated) 473
([M + H]+, found). 1H NMR (400 MHz, CDCl3) δ 8.57−8.48 (m,
1H), 8.21 (d, J = 6.9 Hz, 1H), 8.18−8.08 (m, 2H), 7.91−7.79 (m,
2H), 7.48−7.38 (m, 2H), 7.25−7.14 (m, 4H), 4.76 (h, J = 7.2 Hz,
Figure 3. Co-crystal structure of TNKS2 with 24 (PDB 7O6X). The
protein is shown in blue, and 24 in green. The dashed lines in black
represent hydrogen bonds, and the red spheres represent water
molecules. The σA weighted 2Fo − Fc electron density maps around
the ligands are contoured at 1.8σ.
Figure 4. Compound 24 decreased cell growth and inhibited WNT/β-catenin signaling activity in COLO 320DM cells. (a) 3-(4,5-Dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) colorimetric cell growth assay for various doses of 24 in APCmutated
COLO 320DM (black) and APCwild‑type RKO (gray) cells. After 5 days, the antiproliferative effect of compound treatment was measured at 490 nm.
Mean value ± standard deviation (SD) for one representative experiment of more than three repeated assays, each with six replicates, are shown.
Dotted lines depict 50% (GI50-value) and 25% (GI25-value) growth inhibition levels and control = 100% (0.1% dimethyl sulfoxide (DMSO)). (b)
Representative immunoblots of cytoplasmic TNKS1/2, AXIN1, AXIN2, and cytoplasmic and nuclear transcriptionally active β-catenin (non-
phospho) and β-catenin. Actin and lamin B1 show equal protein loading, while # indicates that the same actin immunoblot is used as loading
control for both AXIN2 and β-catenin. For (b) and (c), control = 0.001% DMSO. (c) Real-time RT-qPCR analyses of WNT/β-catenin signaling
target genes (AXIN2, DKK1, NKD1, and APCDD1). Boxplots show median, first and third quartiles, and maximum and minimum whiskers for
combined data from three independent experiments with three replicates each. Dotted lines depict the control mean value = 1. For (a) and (c),
analysis of variance (ANOVA) tests (Holm−Sidak method, versus control) are indicated by *** (p < 0.001) and * (p < 0.05), while ANOVA on
ranks tests (Dunn’s method, versus control) are indicated by † (p < 0.05).
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1H), 4.54 (h, J = 6.0 Hz, 1H), 3.47 (tt, J = 10.1, 5.8 Hz, 1H), 3.11−
2.97 (m, 2H), 2.52−2.36 (m, 2H), 1.32 (d, J = 6.0 Hz, 6H). HRMS
m/z [M + H]+: 473.20958 (calculated), 473.2089 (found), Δ = −1.42
ppm.
N-(trans-3-(4-(2-Fluorophenyl)-5-phenyl-4H-1,2,4-triazol-3-yl)-
cyclobutyl)picolinamide (9). The title compound was prepared
according to general procedure F as a white solid (21 mg, 84%). LC/
MS (ESI) m/z for C24H20N5OF 413 (calculated) 414 ([M + H]
+,
found). 1H NMR (400 MHz, CDCl3) δ 8.56−8.50 (m, 1H), 8.23 (d, J
= 6.8 Hz, 1H), 8.17 (dt, J = 7.9, 1.1 Hz, 1H), 7.84 (td, J = 7.7, 1.7 Hz,
1H), 7.53−7.46 (m, 1H), 7.46−7.39 (m, 3H), 7.39−7.32 (m, 1H),
7.32−7.27 (m, 2H), 7.26−7.21 (m, 2H), 7.21−7.13 (m, 1H), 4.83−
4.70 (m, 1H), 3.49 (tt, J = 10.2, 5.6 Hz, 1H), 3.11−2.95 (m, 2H),
2.52−2.40 (m, 2H). HRMS m/z [M + H]+: 414.17246 (calculated),
414.1714 (found), Δ = −2.46 ppm.
N-(trans-3-(4-(-2-Fluorophenyl)-5-(pyrazin-2-yl)-4H-1,2,4-tria-
zol-3-yl)cyclobutyl)picolinamide (10). The title compound was
prepared according to general procedure F as a white solid (7.9 mg,
21%). LC/MS (ESI) m/z for C22H18FN7O 415 (calculated) 416 ([M
+ H]+, found). 1H NMR (400 MHz, CDCl3) δ 9.52 (d, J = 1.8 Hz,
1H), 8.53 (d, J = 4.4 Hz, 1H), 8.49 (d, J = 2.5 Hz, 1H), 8.22−8.14
(m, 2H), 7.84 (td, J = 7.7, 1.7 Hz, 1H), 7.54−7.39 (m, 2H), 7.22 (td,
J = 8.1, 7.5, 1.9 Hz, 3H), 4.83−4.74 (m, 1H), 3.52−3.46 (m, 1H),
3.07−3.02 (m, 1H), 2.56−2.41 (m, 2H), 1.55 (s, 2H). HRMS m/z
[M + H]+: 416.16296 (calculated), 416.1620 (found), Δ = −2.40
ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-phenyl-4H-1,2,4-triazol-3-
yl)cyclobutyl)picolinamide (11). The title compound was prepared
according to general procedure F as a white solid (30 mg, 52%). LC/
MS (ESI) m/z for C25H24N6O2 440 (calculated) 441 ([M + H]
+,
found). 1H NMR (400 MHz, CDCl3) δ 8.53 (dq, J = 4.8, 1.1 Hz,
1H), 8.21 (d, J = 7.0 Hz, 1H), 8.16 (dt, J = 7.8, 1.2 Hz, 1H), 8.01 (d, J
= 8.8 Hz, 1H), 7.94 (d, J = 2.9 Hz, 1H), 7.84 (td, J = 7.7, 1.7 Hz, 1H),
7.46−7.38 (m, 4H), 7.21 (dd, J = 8.7, 2.9 Hz, 1H), 7.17−7.12 (m,
2H), 4.76 (h, J = 6.5 Hz, 1H), 4.04 (q, J = 7.0 Hz, 2H), 3.50 (dddd, J
= 10.4, 8.9, 6.2, 5.0 Hz, 1H), 3.09−2.98 (m, 2H), 2.47−2.37 (m, 2H),
1.40 (t, J = 7.0 Hz, 3H). HRMS m/z [M + H]+: 441.20335
(calculated), 441.2025 (found), Δ = −1.86 ppm.
N-(trans-3-(4-(3-Chlorophenyl)-5-(5-ethoxypyridin-2-yl)-4H-
1,2,4-triazol-3-yl)cyclobutyl)picolinamide (12). The title compound
was prepared according to general procedure F as a white solid (14.3
mg, 74%). LC/MS (ESI) m/z for C25H23N6O2Cl 474/476
(calculated) 475/477 ([M + H]+, found). 1H NMR (400 MHz,
CDCl3) δ 8.53 (dt, J = 4.7, 1.3 Hz, 1H), 8.22 (d, J = 7.0 Hz, 1H), 8.17
(dt, J = 7.7, 1.0 Hz, 1H), 8.10 (d, J = 8.7 Hz, 1H), 7.93 (s, 1H), 7.84
(td, J = 7.7, 1.7 Hz, 1H), 7.46−7.40 (m, 2H), 7.36 (t, J = 8.0 Hz, 1H),
7.23 (dd, J = 8.7, 2.7 Hz, 1H), 7.18 (t, J = 2.0 Hz, 1H), 7.07 (dt, J =
8.0, 1.4 Hz, 1H), 4.78 (h, J = 7.0 Hz, 1H), 4.05 (q, J = 7.0 Hz, 2H),
3.53−3.42 (m, 1H), 3.09−2.97 (m, 2H), 2.51−2.39 (m, 2H), 1.41 (t,
J = 7.0 Hz, 3H). HRMS m/z [M + H]+: 475.16438 (calculated),
475.1636 (found), Δ = −1.73 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(5-methylthiophen-2-yl)-
4H-1,2,4-triazol-3-yl)cyclobutyl)picolinamide (13). The title com-
pound was prepared according to general procedure F as a white solid
(19 mg, 85%). LC/MS (ESI) m/z for C24H24N6O2S 460 (calculated)
461 ([M + H]+, found). 1H NMR (400 MHz, CDCl3) δ 8.57−8.52
(m, 1H), 8.25 (d, J = 7.1 Hz, 1H), 8.18 (dt, J = 7.8, 1.1 Hz, 1H), 8.12
(d, J = 2.9 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.85 (td, J = 7.7, 1.7 Hz,
1H), 7.43 (ddd, J = 7.7, 4.8, 1.3 Hz, 1H), 7.22 (dd, J = 8.7, 3.0 Hz,
1H), 6.70 (d, J = 3.6 Hz, 1H), 6.62 (dd, J = 3.6, 1.3 Hz, 1H), 4.78 (q,
J = 7.1 Hz, 1H), 4.08 (q, J = 6.9 Hz, 2H), 3.65−3.56 (m, 1H), 3.11−
3.01 (m, 2H), 2.56−2.49 (m, 2H), 2.47 (d, J = 1.1 Hz, 3H), 1.43 (t, J
= 7.0 Hz, 3H). HRMS m/z [M + H]+: 461.17542 (calculated),
461.1746 (found), Δ = −1.85 ppm.
N-(trans-3-(4-(5-Chlorothiophen-2-yl)-5-(5-ethoxypyridin-2-yl)-
4H-1,2,4-triazol-3-yl)cyclobutyl)picolinamide (14). The title com-
pound was prepared according to general procedure F as a white solid
(14.9 mg, 103%). LC/MS (ESI) m/z for C23H21N6O2SCl 480/482
(calculated) 481/483 ([M + H]+, found). 1H NMR (400 MHz,
CDCl3) δ 8.55 (dt, J = 4.7, 1.4 Hz, 1H), 8.26 (d, J = 6.9 Hz, 1H), 8.18
(dt, J = 7.8, 1.1 Hz, 1H), 8.09 (d, J = 2.9 Hz, 1H), 8.06 (d, J = 8.8 Hz,
1H), 7.85 (td, J = 7.7, 1.7 Hz, 1H), 7.43 (ddd, J = 7.8, 4.7, 1.3 Hz,
1H), 7.25−7.20 (m, 1H), 6.82 (d, J = 4.0 Hz, 1H), 6.72 (d, J = 4.0
Hz, 1H), 4.79 (q, J = 7.2 Hz, 1H), 4.09 (q, J = 6.9 Hz, 2H), 3.63−
3.56 (m, 1H), 3.11−3.01 (m, 2H), 2.59−2.48 (m, 2H), 1.43 (t, J =
7.0 Hz, 3H). HRMS m/z [M + H]+: 481.12080 (calculated),
481.1201 (found), Δ = −1.14 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(pyridin-2-yl)-4H-1,2,4-tri-
azol-3-yl)cyclobutyl)-1,5-naphthyridine-4-carboxamide (16a). The
title compound was prepared according to general procedure F as an
off-white solid (13.7 mg, 55%). LC/MS (ESI) m/z for C27H24N8O2
492 (calculated) 493 ([M + H]+, found). 1H NMR (400 MHz,
CDCl3) δ 11.32 (d, J = 6.0 Hz, 1H), 9.14 (d, J = 4.4 Hz, 1H), 8.99
(dd, J = 4.3, 1.8 Hz, 1H), 8.59−8.52 (m, 3H), 8.17 (d, J = 8.8 Hz,
1H), 7.87 (d, J = 2.9 Hz, 1H), 7.79 (td, J = 7.7, 1.9 Hz, 1H), 7.75 (dd,
J = 8.5, 4.2 Hz, 1H), 7.37 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H), 7.26−7.22
(m, 1H), 7.21−7.16 (m, 1H), 4.86−4.73 (m, 1H), 4.05 (q, J = 6.9 Hz,
2H), 3.80−3.69 (m, 1H), 3.11−3.01 (m, 2H), 2.57−2.46 (m, 2H),
1.41 (t, J = 7.0 Hz, 3H). HRMS m/z [M + H]+: 493.20950
(calculated), 493.2085 (found), Δ = −1.99 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(pyridin-2-yl)-4H-1,2,4-tri-
azol-3-yl)cyclobutyl)-7-fluoro-1,5-naphthyridine-4-carboxamide
(16b). The title compound was prepared according to general
procedure F as a white solid (17.9 mg, 69%). LC/MS (ESI) m/z for
C27H23N8O2F 510 (calculated) 511 ([M + H]
+, found). 1H NMR
(400 MHz, CDCl3) δ 10.81 (d, J = 6.0 Hz, 1H), 9.15 (d, J = 4.5 Hz,
1H), 8.92 (d, J = 2.9 Hz, 1H), 8.56 (dd, J = 5.1, 1.9 Hz, 1H), 8.52 (d,
J = 4.4 Hz, 1H), 8.22−8.18 (m, 1H), 8.17 (d, J = 9.0 Hz, 1H), 7.87
(d, J = 2.8 Hz, 1H), 7.79 (td, J = 7.7, 1.9 Hz, 1H), 7.37 (dd, J = 7.5,
4.8 Hz, 1H), 7.26−7.21 (m, 1H), 7.18 (d, J = 8.0 Hz, 1H), 4.80 (h, J
= 6.9 Hz, 1H), 4.05 (q, J = 7.0 Hz, 2H), 3.72 (tt, J = 10.2, 5.3 Hz,
1H), 3.06 (ddd, J = 13.2, 8.0, 5.3 Hz, 2H), 2.50 (ddd, J = 12.6, 9.5, 6.2
Hz, 2H), 1.41 (t, J = 7.0 Hz, 3H). HRMS m/z [M + H]+: 511.20008
(calculated), 511.1991 (found), Δ = −1.86 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(pyridin-3-yl)-4H-1,2,4-tri-
azol-3-yl)cyclobutyl)-1,5-naphthyridine-4-carboxamide (17a). The
title compound was prepared according to general procedure F as a
white solid (12.6 mg, 50%). LC/MS (ESI) m/z for C27H24N8O2 492
(calculated) 493 ([M + H]+, found). 1H NMR (400 MHz, CDCl3) δ
11.31 (d, J = 6.0 Hz, 1H), 9.14 (d, J = 4.5 Hz, 1H), 8.98 (dd, J = 4.3,
1.8 Hz, 1H), 8.68 (dd, J = 4.8, 1.5 Hz, 1H), 8.59−8.52 (m, 2H), 8.48
(d, J = 2.5 Hz, 1H), 8.17 (d, J = 8.8 Hz, 1H), 7.87 (d, J = 2.9 Hz, 1H),
7.74 (dd, J = 8.6, 4.2 Hz, 1H), 7.58 (ddd, J = 8.1, 2.5, 1.5 Hz, 1H),
7.41 (dd, J = 8.0, 4.7 Hz, 1H), 7.24 (dd, J = 8.7, 2.9 Hz, 1H), 4.86
(dtd, J = 8.7, 6.9, 5.2 Hz, 1H), 4.05 (q, J = 7.0 Hz, 2H), 3.58−3.47
(m, 1H), 3.14−3.03 (m, 2H), 2.62−2.51 (m, 2H), 1.41 (t, J = 7.0 Hz,
3H). HRMS m/z [M + H]+: 493.20950 (calculated), 493.2084
(found), Δ = −2.32 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(pyridin-3-yl)-4H-1,2,4-tri-
azol-3-yl)cyclobutyl)-7-fluoro-1,5-naphthyridine-4-carboxamide
(17b). The title compound was prepared according to general
procedure F as a white solid (22 mg, 85%). LC/MS (ESI) m/z for
C27H23N8O2F 510 (calculated) 511 ([M + H]
+, found). 1H NMR
(400 MHz, CDCl3) δ 10.83 (d, J = 6.0 Hz, 1H), 9.15 (d, J = 4.4 Hz,
1H), 8.91 (d, J = 2.8 Hz, 1H), 8.69 (dd, J = 4.8, 1.5 Hz, 1H), 8.52 (d,
J = 4.4 Hz, 1H), 8.48 (d, J = 2.5 Hz, 1H), 8.23−8.18 (m, 1H), 8.17
(d, J = 8.5 Hz, 1H), 7.87 (d, J = 2.8 Hz, 1H), 7.57 (dt, J = 8.1, 2.0 Hz,
1H), 7.41 (dd, J = 8.2, 4.8 Hz, 1H), 7.26−7.21 (m, 1H), 4.92−4.81
(m, 1H), 4.05 (q, J = 7.0 Hz, 2H), 3.56−3.45 (m, 1H), 3.14−3.03 (m,
2H), 2.60−2.50 (m, 2H), 1.41 (t, J = 7.0 Hz, 3H). HRMS m/z [M +
H]+: 511.20008 (calculated), 511.1991 (found), Δ = −1.95 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(pyridin-4-yl)-4H-1,2,4-tri-
azol-3-yl)cyclobutyl)-1,5-naphthyridine-4-carboxamide (18a). The
title compound was prepared according to general procedure F as a
white solid (12.7 mg, 51%). LC/MS (ESI) m/z for C27H24N8O2 492
(calculated) 493 ([M + H]+, found). 1H NMR (400 MHz, CDCl3) δ
11.31 (d, J = 6.0 Hz, 1H), 9.15 (d, J = 4.4 Hz, 1H), 8.97 (dd, J = 4.3,
1.8 Hz, 1H), 8.75−8.69 (m, 2H), 8.59−8.52 (m, 2H), 8.17 (d, J = 8.8
Hz, 1H), 7.88 (d, J = 2.8 Hz, 1H), 7.74 (dd, J = 8.5, 4.2 Hz, 1H),
7.26−7.22 (m, 1H), 7.17−7.11 (m, 2H), 4.92−4.81 (m, 1H), 4.06 (q,
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J = 7.0 Hz, 2H), 3.58−3.47 (m, 1H), 3.14−3.04 (m, 2H), 2.63−2.52
(m, 2H), 1.42 (t, J = 7.0 Hz, 3H). HRMS m/z [M + H]+: 493.20950
(calculated), 493.2084 (found), Δ = −2.16 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(pyridin-4-yl)-4H-1,2,4-tri-
azol-3-yl)cyclobutyl)-7-fluoro-1,5-naphthyridine-4-carboxamide
(18b). The title compound was prepared according to general
procedure F as a white solid (19.2 mg, 73%). LC/MS (ESI) m/z for
C27H23N8O2F 510 (calculated) 511 ([M + H]
+, found). 1H NMR
(400 MHz, CDCl3) δ 10.83 (d, J = 6.0 Hz, 1H), 9.16 (d, J = 4.5 Hz,
1H), 8.91 (d, J = 2.9 Hz, 1H), 8.76−8.69 (m, 2H), 8.52 (d, J = 4.5
Hz, 1H), 8.20 (dd, J = 8.7, 2.9 Hz, 1H), 8.17 (d, J = 8.6 Hz, 1H),
7.91−7.85 (m, 1H), 7.26−7.22 (m, 1H), 7.17−7.10 (m, 2H), 4.87 (h,
J = 7.1 Hz, 1H), 4.06 (q, J = 6.9 Hz, 2H), 3.56−3.45 (m, 1H), 3.14−
3.03 (m, 2H), 2.62−2.51 (m, 2H), 1.42 (t, J = 7.0 Hz, 3H). HRMS




(19). The title compound was prepared according to general
procedure F as a white solid (12.1 mg, 47%). LC/MS (ESI) m/z
for C28H24N8O2 504 (calculated) 505 ([M + H]
+, found). 1H NMR
(400 MHz, CDCl3) δ 11.46 (s, 1H), 9.14 (d, J = 4.5 Hz, 1H), 9.00
(dd, J = 4.3, 1.7 Hz, 1H), 8.63 (dd, J = 5.1, 1.8 Hz, 1H), 8.55 (dd, J =
8.6, 1.7 Hz, 1H), 8.50 (d, J = 4.4 Hz, 1H), 8.15 (d, J = 8.8 Hz, 1H),
7.87 (td, J = 7.7, 1.9 Hz, 1H), 7.84 (d, J = 3.0 Hz, 1H), 7.75 (dd, J =
8.6, 4.3 Hz, 1H), 7.46 (ddd, J = 7.6, 4.8, 1.0 Hz, 1H), 7.34 (d, J = 7.9
Hz, 1H), 7.21 (dd, J = 8.7, 2.9 Hz, 1H), 4.03 (q, J = 7.0 Hz, 2H), 2.48
(s, 6H), 1.40 (t, J = 7.0 Hz, 3H). HRMS m/z [M + H]+: 505.20950
(calculated), 505.2086 (found), Δ = −1.87 ppm.
N-(3-(5-(5-Ethoxypyridin-2-yl)-4-(pyridin-3-yl)-4H-1,2,4-triazol-3-
yl)bicyclo[1.1.1]pentan-1-yl)-1,5-naphthyridine-4-carboxamide
(20). The title compound was prepared according to general
procedure F as a white solid (20.2 mg, 78%). LC/MS (ESI) m/z
for C28H24N8O2 504 (calculated) 505 ([M + H]
+, found). 1H NMR
(400 MHz, CDCl3) δ 11.45 (s, 1H), 9.14 (d, J = 4.5 Hz, 1H), 8.99
(dd, J = 4.1, 1.8 Hz, 1H), 8.74 (dd, J = 4.8, 1.5 Hz, 1H), 8.58−8.52
(m, 2H), 8.49 (d, J = 4.4 Hz, 1H), 8.14 (d, J = 8.8 Hz, 1H), 7.87 (d, J
= 2.9 Hz, 1H), 7.74 (dd, J = 8.6, 4.3 Hz, 1H), 7.69 (ddd, J = 8.1, 2.5,
1.5 Hz, 1H), 7.46 (dd, J = 8.0, 4.7 Hz, 1H), 7.22 (dd, J = 8.8, 2.9 Hz,
1H), 4.04 (q, J = 6.9 Hz, 2H), 2.49 (s, 6H), 1.40 (t, J = 7.0 Hz, 3H).




(21). The title compound was prepared according to general
procedure F as a white solid (10.2 mg, 62%). LC/MS (ESI) m/z
for C28H24N8O2 504 (calculated) 505 ([M + H]
+, found). 1H NMR
(400 MHz, CDCl3) δ 11.45 (s, 1H), 9.14 (d, J = 4.5 Hz, 1H), 8.99
(dd, J = 4.2, 1.8 Hz, 1H), 8.82−8.75 (m, 2H), 8.55 (dd, J = 8.6, 1.8
Hz, 1H), 8.50 (d, J = 4.4 Hz, 1H), 8.14 (d, J = 8.8 Hz, 1H), 7.86 (d, J
= 2.8 Hz, 1H), 7.74 (dd, J = 8.5, 4.2 Hz, 1H), 7.27 (d, J = 1.7 Hz,
2H), 7.23 (dd, J = 8.7, 2.9 Hz, 1H), 4.04 (q, J = 6.9 Hz, 2H), 2.51 (s,
6H), 1.41 (t, J = 7.0 Hz, 3H). HRMS m/z [M + H]+: 505.20950
(calculated), 505.2085 (found), Δ = −2.02 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(5-methylthiophen-2-yl)-
4H-1,2,4-triazol-3-yl)cyclobutyl)-1,5-naphthyridine-4-carboxamide
(22a). The title compound was prepared according to general
procedure F as a white solid (8.4 mg, 33%). LC/MS (ESI) m/z for
C27H25N7O2S 511 (calculated) 512 ([M + H]
+, found). 1H NMR
(400 MHz, CDCl3) δ 11.31 (d, J = 6.0 Hz, 1H), 9.15 (d, J = 4.4 Hz,
1H), 9.00 (dd, J = 4.3, 1.8 Hz, 1H), 8.60−8.53 (m, 2H), 8.12 (d, J =
2.8 Hz, 1H), 7.97 (d, J = 8.7 Hz, 1H), 7.75 (dd, J = 8.5, 4.2 Hz, 1H),
7.23−7.20 (m, 1H), 6.72 (d, J = 3.7 Hz, 1H), 6.61 (dd, J = 3.7, 1.3
Hz, 1H), 4.86 (q, J = 7.0 Hz, 1H), 4.08 (q, J = 7.0 Hz, 2H), 3.72−
3.62 (m, 1H), 3.16−3.05 (m, 2H), 2.69−2.58 (m, 2H), 2.47 (d, J =
1.1 Hz, 3H), 1.43 (t, J = 7.0 Hz, 3H). HRMS m/z [M + H]+:
512.18632 (calculated), 512.1854 (found), Δ = −1.73 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(5-methylthiophen-2-yl)-
4H-1,2,4-triazol-3-yl)cyclobutyl)-7-fluoro-1,5-naphthyridine-4-car-
boxamide (22b). The title compound was prepared according to
general procedure F as a white solid (13 mg, 43%). LC/MS (ESI) m/
z for C27H24N7O2SF 529 (calculated) 530 ([M + H]
+, found). 1H
NMR (400 MHz, CDCl3) δ 10.84 (d, J = 6.0 Hz, 1H), 9.16 (d, J = 4.4
Hz, 1H), 8.93 (d, J = 2.9 Hz, 1H), 8.54 (d, J = 4.4 Hz, 1H), 8.20 (dd,
J = 8.7, 2.9 Hz, 1H), 8.12 (d, J = 2.9 Hz, 1H), 7.97 (d, J = 8.8 Hz,
1H), 7.23−7.19 (m, 1H), 6.72 (d, J = 3.7 Hz, 1H), 6.65−6.59 (m,
1H), 4.94−4.82 (m, 1H), 4.08 (q, J = 7.1 Hz, 2H), 3.72−3.60 (m,
1H), 3.15−3.06 (m, 2H), 2.66−2.57 (m, 2H), 2.47 (d, J = 1.1 Hz,
3H), 1.43 (t, J = 7.0 Hz, 3H). HRMS m/z [M + H]+: 530.17690
(calculated), 530.1761 (found), Δ = −1.59 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(5-methylthiophen-2-yl)-
4H-1,2,4-triazol-3-yl)cyclobutyl)quinoline-8-carboxamide (23). The
title compound was prepared according to general procedure F as a
white solid (12 mg, 41%). LC/MS (ESI) m/z for C28H26N6O2S 510
(calculated) 511 ([M + H]+, found). 1H NMR (400 MHz, CDCl3) δ
11.57 (d, J = 5.9 Hz, 1H), 8.94 (dd, J = 4.2, 1.9 Hz, 1H), 8.85 (dd, J =
7.4, 1.6 Hz, 1H), 8.29 (dd, J = 8.3, 1.8 Hz, 1H), 8.12 (d, J = 2.8 Hz,
1H), 7.96 (dd, J = 8.3, 1.6 Hz, 2H), 7.68 (t, J = 7.7 Hz, 1H), 7.53−
7.47 (m, 1H), 7.22−7.19 (m, 1H), 6.72 (d, J = 3.7 Hz, 1H), 6.63−
6.58 (m, 1H), 4.83 (q, J = 7.0 Hz, 1H), 4.08 (q, J = 7.0 Hz, 2H),
3.77−3.60 (m, 1H), 3.12−3.06 (m, 2H), 2.67−2.60 (m, 2H), 2.46 (d,
J = 1.2 Hz, 3H), 1.43 (t, J = 6.9 Hz, 3H). HRMS m/z [M + H]+:
511.19107 (calculated), 511.1902 (found), Δ = −1.63 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(2-fluorophenyl)-4H-1,2,4-
triazol-3-yl)cyclobutyl)quinoxaline-5-carboxamide (24, OM-153).
The title compound was prepared according to general procedure F as
a white solid (20.4 mg, 79%). LC/MS (ESI) m/z for C28H24N7O2F
509 (calculated) 510 ([M + H]+, found). 1H NMR (400 MHz,
CDCl3) δ 10.68 (d, J = 5.9 Hz, 1H), 8.97 (d, J = 1.9 Hz, 1H), 8.89−
8.83 (m, 2H), 8.26 (dd, J = 8.3, 1.6 Hz, 1H), 8.16 (d, J = 8.7 Hz, 1H),
7.94−7.86 (m, 2H), 7.47−7.39 (m, 1H), 7.25−7.13 (m, 4H), 4.83
(dqd, J = 8.5, 6.8, 5.3 Hz, 1H), 4.04 (q, J = 7.0 Hz, 2H), 3.53 (dp, J =
10.1, 5.5 Hz, 1H), 3.08 (dtd, J = 12.0, 5.8, 3.9 Hz, 2H), 2.53 (ddtt, J =
19.4, 9.6, 6.2, 3.0 Hz, 2H), 1.40 (t, J = 7.0 Hz, 3H). HRMS m/z [M +
H]+: 510.20483 (calculated), 510.2040 (found), Δ = −1.66 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(2-fluorophenyl)-4H-1,2,4-
triazol-3-yl)cyclobutyl)-7-fluoroquinoxaline-5-carboxamide (25).
The title compound was prepared according to general procedure F
as a white solid (18.2 mg, 68%). LC/MS (ESI) m/z for C28H23N7O2F
527 (calculated) 528 ([M + H]+, found). 1H NMR (400 MHz,
CDCl3) δ 10.62 (d, J = 5.8 Hz, 1H), 8.96 (d, J = 1.8 Hz, 1H), 8.82 (d,
J = 1.9 Hz, 1H), 8.64 (dd, J = 9.6, 3.1 Hz, 1H), 8.24−8.11 (m, 1H),
7.87 (dd, J = 7.9, 3.1 Hz, 2H), 7.48−7.39 (m, 1H), 7.25−7.14 (m,
4H), 4.83 (h, J = 6.8 Hz, 1H), 4.04 (q, J = 6.9 Hz, 2H), 3.57−3.46
(m, 1H), 3.13−3.01 (m, 2H), 2.60−2.45 (m, 2H), 1.40 (t, J = 6.9 Hz,
3H). HRMS m/z [M + H]+: 528.19541 (calculated), 528.1946
(found), Δ = −1.59 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(2-fluorophenyl)-4H-1,2,4-
triazol-3-yl)cyclobutyl)-3-methylquinoxaline-5-carboxamide (26).
The title compound was prepared according to general procedure F
as a slightly pink solid (93.1 mg, 65%). LC/MS (ESI) m/z for
C29H26N7O2F 523 (calculated) 524 ([M + H]
+, found). 1H NMR
(400 MHz, DMSO) δ 10.42 (d, J = 7.1 Hz, 1H), 8.98 (s, 1H), 8.41
(dd, J = 7.3, 1.5 Hz, 1H), 8.21 (dd, J = 8.3, 1.5 Hz, 1H), 8.06 (d, J =
8.7 Hz, 1H), 7.94 (d, J = 3.0 Hz, 1H), 7.87 (dd, J = 8.3, 7.3 Hz, 1H),
7.61−7.53 (m, 2H), 7.50 (dd, J = 8.8, 3.0 Hz, 1H), 7.47−7.39 (m,
1H), 7.36−7.29 (m, 1H), 4.75 (q, J = 7.3 Hz, 1H), 4.10 (q, J = 7.0
Hz, 2H), 3.40 (dt, J = 9.4, 4.6 Hz, 1H), 2.92−2.82 (m, 1H), 2.75 (s,
3H), 2.72−2.66 (m, 1H), 2.45−2.29 (m, 2H), 1.31 (t, J = 6.9 Hz,
3H). HRMS m/z [M + H]+: 524.22048 (calculated), 524.2197
(found), Δ = −1.56 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(2-fluorophenyl)-4H-1,2,4-
triazol-3-yl)cyclobutyl)-2-methylquinoxaline-5-carboxamide (27).
The title compound was prepared according to general procedure F
as an off-white solid (20.1 mg, 71%). LC/MS (ESI) m/z for
C29H26N7O2F 523 (calculated) 524 ([M + H]
+, found). 1H NMR
(400 MHz, DMSO) δ 10.42 (d, J = 7.1 Hz, 1H), 8.98 (s, 1H), 8.41
(dd, J = 7.3, 1.6 Hz, 1H), 8.21 (dd, J = 8.4, 1.5 Hz, 1H), 8.06 (d, J =
8.8 Hz, 1H), 7.93 (d, J = 2.8 Hz, 1H), 7.91−7.84 (m, 1H), 7.63−7.52
(m, 2H), 7.50 (dd, J = 8.8, 3.0 Hz, 1H), 7.47−7.39 (m, 1H), 7.36−
7.29 (m, 1H), 4.75 (q, J = 7.2 Hz, 1H), 4.10 (q, J = 7.0 Hz, 2H),
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://doi.org/10.1021/acs.jmedchem.1c01264
J. Med. Chem. XXXX, XXX, XXX−XXX
I
3.44−3.36 (m, 1H), 2.87 (q, J = 3.8 Hz, 1H), 2.75 (s, 3H), 2.68 (s,
1H), 2.45−2.28 (m, 2H), 1.31 (t, J = 6.9 Hz, 3H). HRMS m/z [M +
H]+: 524.22048 (calculated), 524.2198 (found), Δ = −1.36 ppm.
N-(trans-3-(5-(5-Ethoxypyridin-2-yl)-4-(2-fluorophenyl)-4H-1,2,4-
triazol-3-yl)cyclobutyl)-2,3-dimethylquinoxaline-5-carboxamide
(28). The title compound was prepared according to general
procedure F as an off-white solid (29.7 mg, 43%). LC/MS (ESI)
m/z for C30H28N7O2F 537 (calculated) 538 ([M + H]
+, found). 1H
NMR (400 MHz, DMSO) δ 10.59 (d, J = 7.2 Hz, 1H), 8.36 (dd, J =
7.4, 1.6 Hz, 1H), 8.18−8.01 (m, 2H), 7.94 (d, J = 3.0 Hz, 1H), 7.82
(t, J = 7.8 Hz, 1H), 7.56 (td, J = 8.2, 3.1 Hz, 2H), 7.50 (dd, J = 8.8,
2.9 Hz, 1H), 7.43 (t, J = 9.2 Hz, 1H), 7.33 (t, J = 7.7 Hz, 1H), 4.75
(q, J = 7.2 Hz, 1H), 4.10 (q, J = 7.0 Hz, 2H), 2.86 (d, J = 9.7 Hz, 1H),
2.72 (d, J = 3.6 Hz, 7H), 2.45−2.28 (m, 2H), 1.31 (t, J = 7.0 Hz, 3H).




(29a). The title compound was prepared according to general
procedure F as a white solid (23 mg, 86%). LC/MS (ESI) m/z for
C27H20N7O2F3 531 (calculated) 532 ([M + H]
+, found). 1H NMR
(400 MHz, CDCl3) δ 10.67 (d, J = 5.9 Hz, 1H), 8.97 (d, J = 1.8 Hz,
1H), 8.89−8.83 (m, 2H), 8.33 (d, J = 8.8 Hz, 1H), 8.26 (dd, J = 8.4,
1.6 Hz, 1H), 8.07 (d, J = 2.8 Hz, 1H), 7.90 (dd, J = 8.4, 7.4 Hz, 1H),
7.55 (dd, J = 8.8, 2.8 Hz, 1H), 7.51−7.42 (m, 1H), 7.26−7.16 (m,
3H), 6.52 (t, J = 72.5 Hz, 1H), 4.90−4.79 (m, 1H), 3.57−3.47 (m,
1H), 3.14−3.02 (m, 2H), 2.63−2.47 (m, 2H). HRMS m/z [M + H]+:
532.17033 (calculated), 532.1692 (found), Δ = −2.12 ppm.
N-(trans-3-(5-(5-(2,2-Difluoroethoxy)pyridin-2-yl)-4-((S)-2-fluoro-
phenyl)-4H-1,2,4-triazol-3-yl)cyclobutyl)-7-fluoroquinoxaline-5-
carboxamide (29b). The title compound was prepared according to
general procedure F as a white solid (19.8 mg, 71%). LC/MS (ESI)
m/z for C27H19N7O2F4 549 (calculated) 550 ([M + H]
+, found). 1H
NMR (400 MHz, CDCl3) δ 10.63 (d, J = 5.9 Hz, 1H), 8.96 (d, J = 2.0
Hz, 1H), 8.82 (d, J = 1.9 Hz, 1H), 8.64 (dd, J = 9.5, 3.1 Hz, 1H), 8.33
(d, J = 8.7 Hz, 1H), 8.07 (d, J = 2.6 Hz, 1H), 7.87 (dd, J = 7.8, 3.1 Hz,
1H), 7.55 (dd, J = 8.8, 2.8 Hz, 1H), 7.51−7.42 (m, 1H), 7.25−7.16
(m, 3H), 6.52 (t, J = 72.5 Hz, 1H), 4.91−4.79 (m, 1H), 3.56−3.45
(m, 1H), 3.14−3.01 (m, 2H), 2.62−2.47 (m, 2H). HRMS m/z [M +
H]+: 550.16091 (calculated), 550.1597 (found), Δ = −2.25 ppm.
N-(trans-3-(4-(2-Fluorophenyl)-5-(pyridin-2-yl)-4H-1,2,4-triazol-
3-yl)cyclobutyl)quinoxaline-5-carboxamide (30a). The title com-
pound was prepared according to general procedure F as a white solid
(19.3 mg, 83%). LC/MS (ESI) m/z for C26H20N7OG 465
(calculated) 466 ([M + H]+, found). 1H NMR (400 MHz, CDCl3)
δ 10.68 (d, J = 5.8 Hz, 1H), 8.97 (d, J = 1.8 Hz, 1H), 8.89−8.83 (m,
2H), 8.26 (dd, J = 8.3, 1.5 Hz, 2H), 8.24−8.18 (m, 1H), 7.94−7.87
(m, 1H), 7.76 (td, J = 7.8, 1.7 Hz, 1H), 7.49−7.40 (m, 1H), 7.25−
7.14 (m, 4H), 4.90−4.78 (m, 1H), 3.59−3.49 (m, 1H), 3.15−3.03
(m, 2H), 2.62−2.47 (m, 2H). HRMS m/z [M + H]+: 466.17861
(calculated), 466.1775 (found), Δ = −2.34 ppm.
N-(trans-3-(5-(5-(6-Methylpyridin-2-yl)-4-(S)-2-fluorophenyl)-4H-
1,2,4-triazol-3-yl)cyclobutyl)-7-fluoroquinoxaline-5-carboxamide
(30b). The title compound was prepared according to general
procedure F as a white solid (16 mg, 65%). LC/MS (ESI) m/z for
C26H19N7OF2 483 (calculated) 484 ([M + H]
+, found). 1H NMR
(400 MHz, CDCl3) δ 10.63 (d, J = 5.8 Hz, 1H), 8.96 (d, J = 1.8 Hz,
1H), 8.83 (d, J = 1.8 Hz, 1H), 8.64 (dd, J = 9.6, 3.1 Hz, 1H), 8.26 (dt,
J = 8.1, 1.1 Hz, 1H), 8.22 (dd, J = 4.8, 1.6 Hz, 1H), 7.87 (dd, J = 7.8,
3.1 Hz, 1H), 7.76 (td, J = 7.8, 1.8 Hz, 1H), 7.49−7.40 (m, 1H), 7.25−
7.14 (m, 4H), 4.84 (ht, J = 7.1, 1.5 Hz, 1H), 3.53 (tt, J = 9.3, 5.3 Hz,
1H), 3.14−3.02 (sym. m, 2H), 2.55 (dddd, J = 16.5, 13.1, 9.8, 6.5 Hz,
2H). HRMS m/z [M + H]+: 484.16919 (calculated), 484.1684
(found), Δ = −1.65 ppm.
N-(trans-3-(4-(2-Fluorophenyl)-5-(6-methylpyridin-2-yl)-4H-
1,2,4-triazol-3-yl)cyclobutyl)quinoxaline-5-carboxamide (31a).
The title compound was prepared according to general procedure F
as a white solid (20.7 mg, 86%). LC/MS (ESI) m/z for C27H22N7OF
479 (calculated) 480 ([M + H]+, found). 1H NMR (400 MHz,
CDCl3) δ 10.68 (d, J = 5.7 Hz, 1H), 8.96 (d, J = 1.9 Hz, 1H), 8.90−
8.82 (m, 2H), 8.26 (dd, J = 8.4, 1.6 Hz, 1H), 8.07 (d, J = 7.8 Hz, 1H),
7.90 (dd, J = 8.4, 7.4 Hz, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.49−7.41 (m,
1H), 7.26−7.14 (m, 3H), 7.03 (d, J = 7.7 Hz, 1H), 4.89−4.78 (m,
1H), 3.61−3.50 (m, 1H), 3.15−3.05 (m, 2H), 2.62−2.48 (m, 2H),
2.07 (s, 3H). HRMS m/z [M + H]+: 480.19426 (calculated),
480.1934 (found), Δ = −1.75 ppm.
N-(trans-3-(4-(2-Fluorophenyl)-5-(6-methylpyridin-2-yl)-4H-
1,2,4-triazol-3-yl)cyclobutyl)-7-fluoroquinoxaline-5-carboxamide
(31b). The title compound was prepared according to general
procedure F as a white solid (18.2 mg, 72%). LC/MS (ESI) m/z for
C27H21N7OF2 497 (calculated) 498 ([M + H]
+, found). 1H NMR
(400 MHz, CDCl3) δ 10.63 (d, J = 5.9 Hz, 1H), 8.96 (d, J = 1.9 Hz,
1H), 8.83 (d, J = 1.8 Hz, 1H), 8.64 (dd, J = 9.5, 3.1 Hz, 1H), 8.06 (d,
J = 7.8 Hz, 1H), 7.87 (dd, J = 7.8, 3.1 Hz, 1H), 7.63 (t, J = 7.8 Hz,
1H), 7.49−7.41 (m, 1H), 7.24−7.15 (m, 3H), 7.03 (d, J = 7.7 Hz,
1H), 4.91−4.78 (m, 1H), 3.60−3.49 (m, 1H), 3.15−3.03 (m, 2H),
2.62−2.48 (m, 2H), 2.07 (s, 3H). HRMS m/z [M + H]+: 498.18484
(calculated), 498.1838 (found), Δ = −2.11 ppm.
Biochemical Assay. Recombinantly expressed human tankyrase
active constructs for TNKS1 (residues 1030−1317) and TNKS2
(residues 873−1162) and other PARP enzymes used for biochemical
assays were produced as previously described.39 The enzymatic assay
measures unreacted NAD+, which is chemically reacted into a
fluorescent compound.53 The fluorescence intensity was measured
with excitation/emission wavelengths of 372 and 444 nm,
respectively, using Tecan Infinity M1000 Pro. New compounds
were prepared in half-log dilution series, and the reactions were
carried out in quadruplicates with protein and compound controls to
exclude the effect of compound autofluorescence. All reactions were
performed at ambient temperature. TNKS1 (20 nM) or TNKS2 (5
nM) was incubated for 20 h in assay buffer (50 mM Bis-Tris propane
(BTP), pH 7.0, 0.5 mM Tris(2-carboxyethyl)phosphine (TCEP),
0.01% Triton X-100) with compound and 10 μM or 500 nM NAD+,
respectively.
The assay conditions for the other PARP enzymes were used as
previously described.39 Reference compound OD336 behaved in this
assay as previously reported.28
For single IC50 curves, the 95% confidence interval (asymptotic)
was calculated in GraphPad Prism 8.
WNT/β-Catenin Signaling Reporter Assay. The luciferase
based WNT/β-catenin signaling pathway reporter assay in human
HEK293 cells was performed in triplicates as previously described21
also taking OD336 as a reference compound, which behaved in this
assay as previously described.28
ADME. Kinetic solubility, microsomal stability, and plasma stability
were determined following our internal protocol (Symeres). The
Caco-2 and PPB determinations were performed by Cyprotex.
Off-Target. A safety panel (Cerep) of 44 selected targets (n = 2)
including hERG Inhibition using 10 μM 24 was performed by
Eurofins. Ames and CYP3A4 inhibition assays were performed by
Cyprotex, and the PXR assay (CYP induction) was performed at
Admescope. The PARP assays are described below.
Mouse Pharmacokinetic Analysis. The pharmacokinetic
analyses in mice were performed according to the standard protocols
of Medicilon as previously described21 following approval by local
animal experiment authorities (Shanghai, China) and in compliance
with FELASA guidelines and recommendations. Three IRC mice
were used per treatment group: 5 mg/kg 24 in 5% DMSO, 50%
PEG400 (both Sigma-Aldrich), and 45% saline as vehicle. Samples
were collected after 5, 15, and 30 min and 1, 2, 4, 8, and 24 h.
Crystallography. The co-crystallization of human TNKS2
catalytic domain (residues 952−1161) in complex with 24 was
done in the presence of chymotrypsin (1:100) and based on
crystallization efforts previously described.39 Protein (5.3 mg/mL)
was mixed with 0.4 mM compound from a 10 mM stock solution in
DMSO. The droplets for crystallization were set up using the sitting-
drop vapor diffusion method by mixing 200 nL of protein with 100 nL
of precipitant solution (0.1 M Bicine, pH 8.5−9.0, 7.5−25%
PEG6000). All steps were performed at room temperature. Rod-
shaped crystals appeared within 24 h and were cryoprotected using
the precipitant solution containing 25% PEG6000 and 20% glycerol.
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Data were collected at Diamond Light Source on beamline I04.
Diffraction data were processed using the XDS package.54 The
substructure was solved using molecular replacement with PHASER55
using the structure of TNKS2 (PDB code: 5NOB) as starting model.
Model building and refinement was done using Coot56 and
Refmac5,57 respectively. Preparation of the crystal structure images
was done with The PyMOL Molecular Graphics System (PyMOL,
version 1.8.4.0).
Proliferation Assay. Antiproliferative assays using colon cancer
cell lines COLO 320DM and RKO were performed as previously
described.39
Western Blot Analysis. Western blot analysis of nuclear and
cytoplasmic lysates from compound-treated COLO 320DM cells was
performed as previously described.39,50
RNA Isolation and Real-Time qRT-PCR. RNA isolation and
real-time qRT-PCR were performed as previously described.39,50
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ADME, absorption, distribution, metabolism, and excretion;
ADP, adenosine 5′-diphosphate; AKT, serine/threonine
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human ether-a-̀go-go-related gene; LC/MS, liquid chromatog-
raphy/mass spectroscopy; MTS, 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium; NKD1, NKD inhibitor of WNT signaling pathway 1;
NAD, nicotinamide adenine dinucleotide; NMR, nuclear
magnetic resonance; PARP, poly-ADP-ribose polymerase;
PARsylate, poly(ADP-ribose)sylate; PGC-1α, peroxisome
proliferator-activated receptor-γ coactivator 1 α; PK, pharma-
cokinetics; PO, per oral; PPB, plasma protein binding; PTEN,
phosphatase and tensin homolog; RT-qPCR, reverse tran-
scription quantitative polymerase chain reaction; RNF146, ring
finger protein 146; SD, standard deviation; SEM, standard
error of the mean; SH3BP2, sarcoma homology 3 (SH3)
domain binding protein 2; SOX9, sex-determining region Y
(SRY)-box transcription factor 9; t1/2, half-life; TNKS,
telomeric repeat factor (TRF1)-interacting ankyrin-related
ADP-ribose polymerases, tankyrase; TNKS1/2, tankyrase 1
and tankyrase 2; tPSA, total polar surface area; TRF, telomeric
repeat factor; Vd, volume of distribution; WNT, wingless-type
mammary tumor virus integration site
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